Axsome Therapeutics' (AXSM) Overweight Rating Reiterated at Cantor Fitzgerald

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report)'s stock had its "overweight" rating reissued by analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports. They currently have a $153.00 price target on the stock. Cantor Fitzgerald's price objective would suggest a potential upside of 11.07% from the company's current price. Cantor Fitzgerald also issued estimates for Axsome Therapeutics' FY2025 earnings at ($4.15) EPS.

A number of other analysts also recently weighed in on AXSM. Robert W. Baird increased their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Mizuho increased their price target on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the company an "outperform" rating in a report on Tuesday, February 11th. Leerink Partners increased their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a report on Monday, February 10th. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price objective for the company. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $155.47.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM traded up $8.65 during trading hours on Wednesday, hitting $137.75. 1,483,178 shares of the stock were exchanged, compared to its average volume of 1,102,240. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.37. The company's 50 day moving average is $100.34 and its 200 day moving average is $94.46. The firm has a market capitalization of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05. Axsome Therapeutics has a one year low of $64.11 and a one year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, research analysts expect that Axsome Therapeutics will post -2.26 EPS for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 22.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BVF Inc. IL boosted its stake in Axsome Therapeutics by 32.7% during the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock worth $117,444,000 after acquiring an additional 342,064 shares during the last quarter. FMR LLC boosted its stake in Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company's stock worth $97,786,000 after acquiring an additional 185,951 shares during the last quarter. Geode Capital Management LLC lifted its stake in Axsome Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock valued at $77,228,000 after buying an additional 4,079 shares in the last quarter. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock valued at $66,750,000 after buying an additional 8,125 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in Axsome Therapeutics by 10.8% in the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company's stock valued at $58,589,000 after buying an additional 67,285 shares in the last quarter. Institutional investors own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.